Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products.
New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE: CC) and certain of the company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
Key Details of the Chemours ($CC) Class Action:
Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products Stock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rightsInvestors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.
Why is Chemours Being Sued for Securities Fraud?
Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.
According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by "higher . . . demand" in its Opteon segment.
As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an "oversupplied channel heading into 2026."
Why did Chemours's Stock Drop?
On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had "built additional inventory" of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an "oversupplied channel heading into 2026."
On this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.
Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
What Can You Do?
If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - October 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company ("The Chemours" or the "Company") (NYSE: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results, including a reduction of its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously), and management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding The Chemours' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the The Chemours class action, go to www.faruqilaw.com/CC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the The Chemours Securities Class Action Lawsuit:
What is the The Chemours securities fraud lawsuit about?
The lawsuit alleges that The Chemours Company ("Chemours") and certain of its officers and directors made materially false and/or misleading statements and failed to disclose material information to investors during the Class Period. Specifically, the complaint alleges that Defendants materially overstated aftermarket demand for their Opteon products and concealed that demand was declining due to Defendants' alleged overselling of those products in the preceding fiscal year. As a result of these allegedly undisclosed issues, the complaint further alleges that Defendants' financial guidance for fiscal year 2026 was unreliable. On August 4, 2026, after market hours, Chemours allegedly revealed the truth when it announced reduced full-year adjusted EBITDA guidance and management acknowledged that aftermarket customers had built excess inventory following an initial channel fill, creating an oversupplied channel heading into 2026.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired the common stock of The Chemours Company (NYSE: CC) on the open market between February 20, 2026 and August 4, 2026, inclusive, may be eligible to participate in this lawsuit. The class period encompasses all qualifying purchases made during those dates, and eligible investors are encouraged to review the complaint and assess their potential claims. Importantly, investors do not need to seek appointment as lead plaintiff in order to participate in the case or share in any potential recovery. Any investor who believes they may have suffered losses as a result of the alleged misconduct is encouraged to contact counsel to learn more about their rights and options.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy and the selection of counsel. Any member of the proposed class may move the court for appointment as lead plaintiff, and the court will typically appoint the applicant or group of applicants who demonstrate the largest financial interest in the relief sought and who otherwise satisfy the requirements of the applicable law. The deadline to file a motion for appointment as lead plaintiff in this action is December 7, 2026. Critically, an investor need not serve as lead plaintiff to be a member of the class or to share in any recovery that may be obtained; class membership and any resulting recovery are available to all eligible investors regardless of whether they seek a leadership role in the case.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased The Chemours securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320204
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.
Chemours Case Details
The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:
(1) Defendants had materially overstated aftermarket demand for their Opteon products;
(2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year;
(3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and
(4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
What's Next for Chemours Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Chemours Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
The Chemours Company Securities Fraud Class Action Result of Overstatement of Refrigerant Aftermarket Demand and 18% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCPR Newswire
NEW YORK and NEW ORLEANS, Oct. 23, 2026
, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.
What You May Do
If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026.
>>>CLICK HERE for more information
About the Lawsuit
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."
On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.
>>>To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
>>>For More Information about the case, Click HERE
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-securities-fraud-class-action-result-of-overstatement-of-refrigerant-aftermarket-demand-and-18-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918520.html
, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.
What You May Do
If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026.
>>>CLICK HERE for more information
About the Lawsuit
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."
On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.
>>>To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
>>>For More Information about the case, Click HERE
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Chemours and have suffered losses, you may CLICK HERE to contact us.
LOS ANGELES, Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors of upcoming lead plaintiff deadlines in securities class action lawsuits filed on behalf of shareholders of The Chemours Company, Compass, Inc., and Millrose Properties, Inc. Investors who wish to seek appointment as lead plaintiff must file a motion by the deadlines listed below.
If you lost money on these investments, contact The Law Offices of Frank R. Cruz about these class actions to learn about your legal rights, by calling 310-914-5007 or emailing [email protected].
The Chemours Company (NYSE: CC)
Class period: February 20, 2026 through August 4, 2026Lead plaintiff motion deadline: December 7, 2026Case: Darcy v. The Chemours Company et al., filed in the U.S. District Court District of Delaware (Wilmington) According to the Chemours Company complaint, throughout the class period the defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; and (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable.
If you are a The Chemours Company shareholder who suffered a loss, click here to participate.
Compass, Inc. (NYSE: COMP)
Class period: January 9, 2026 through October 7, 2026Lead plaintiff motion deadline: December 8, 2026Case: Magloire v. Compass, Inc. et al., filed in the U.S. District Court Southern District of New York According to the Compass, Inc. complaint, throughout the class period the defendants made false and/or misleading statements and/or failed to disclose that: (i) Compass and Anywhere failed to “use their respective reasonable best efforts to obtain [] authorizations and consents” from “certain regulatory authorities” and “to take, or cause to be taken, all appropriate actions and . . . all things necessary, proper or advisable under applicable law (including any antitrust laws) to consummate and make effective the merger at the earliest practicable date”; (ii) Compass was not in “compliance with applicable laws,” with “the absence of governmental investigations and the possession of and compliance with licenses and permits necessary for the conduct of business.”; and (iii) Defendants hired a well-connected lobbyist and lawyer to obtain access to high-level Department of Justice officials to circumvent the antitrust merger review process.
If you are a Compass, Inc. shareholder who suffered a loss, click here to participate.
Millrose Properties, Inc. (NYSE: MRP)
Class period: February 7, 2025 through October 2, 2026Lead plaintiff motion deadline: December 8, 2026Case: Rubenstsein et al. v. Millrose Properties, Inc. et al., filed in the U.S. District Court for the Southern District of Florida According to the Millrose Properties, Inc. complaint, throughout the class period the defendants made false and/or misleading statements and/or failed to disclose that: (i) despite representations to the contrary, Millrose's objectives were not limited to engaging in land purchases, horizontal development, and homesite option purchase arrangements for Lennar and potentially other homebuilders and developers; (ii) despite representations to the contrary, Millrose would in fact enter into lease agreements and would have tenants in its properties; (iii) Millrose would purchase $200 million worth of properties from Lennar; and (iv) Millrose would lease the properties purchased from Lennar out at a loss.
If you are a Millrose Properties, Inc. shareholder who suffered a loss, click here to participate.
What should investors in these cases do now?
Investors need not take any action at this time to be class members in these cases. Investors may retain counsel of their choice or take no action and remain absent class members. No class has been certified yet in any of these cases.
For more information about these class actions or your rights, contact Frank R. Cruz of The Law Offices of Frank R. Cruz at 310-914-5007, by email at [email protected], or visit the firm's case page.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
About The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.
BENSALEM, Pa.--(BUSINESS WIRE)--The Chemours Company ("Chemours" or the "Company") (NYSE: CC) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 7, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 20, 2026 through August 4, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Darcy v. The Chemours Compan.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
Key Details of the Chemours ($CC) Class Action:
Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon productsStock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rights
Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.
Why is Chemours Being Sued for Securities Fraud?
Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.
According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the “sustained double-digit” Opteon expansion would be “driven by the continued regulatory adoption” of the AIM Act. What’s more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by “higher . . . demand” in its Opteon segment.
As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an “oversupplied channel heading into 2026.”
Why did Chemours’s Stock Drop?
On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had “built additional inventory” of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an “oversupplied channel heading into 2026.”
On this news, Chemours’s stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.
Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
What Can You Do?
If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
LOS ANGELES, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Investors in The Chemours Company ("Chemours" or the "Company") (NYSE: CC) have until December 7, 2026 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline. The Chemours Company case, Darcy v. The Chemours Company et al., was filed on October 8, 2026 and is pending in the U.S. District Court District of Delaware (Wilmington) (Case No. 1:26-cv-01299).
Investors who suffered losses on The Chemours Company investments can contact Glancy about the Chemours Company class action to learn about potentially pursuing claims under the federal securities laws before the December 7, 2026 deadline.
Deadline and key dates for The Chemours Company investors
Lead plaintiff deadline: December 7, 2026Class period: February 20, 2026 to August 4, 2026, inclusiveComplaint filed: October 8, 2026Court: U.S. District Court District of Delaware (Wilmington) What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What does the Chemours Company complaint allege?
The Chemours Company securities lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Investors who purchased or otherwise acquired The Chemours Company securities during the class period may move the Court no later than December 7, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.
"The complaint filed against The Chemours Company alleges that, among other things, the Company failed to disclose that Defendants had materially overstated aftermarket demand for their Opteon products. Investors who want to help lead this case must ask the Court by December 7, 2026, and that date is coming soon," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm that can help The Chemours Company investors evaluate potential claims to recover their losses. Investors who wish to serve as lead plaintiff in the Chemours Company class action must move the Court by December 7, 2026. To learn more, visit the Chemours Company case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
To be a member of the Chemours Company class, you need not take any action at this time. You may retain counsel of your choice or take no action and remain an absent class member. No class has been certified yet in the Chemours Company case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026 and suffered losses may be members of the proposed class in the Chemours Company shareholder lawsuit.
When is the Chemours Company lead plaintiff deadline? Motions to serve as lead plaintiff in the Chemours Company class action must be filed with the U.S. District Court District of Delaware (Wilmington) by December 7, 2026.
What if I miss the Chemours Company deadline? After December 7, 2026, investors generally can no longer ask to be appointed lead plaintiff, but The Chemours Company investors may still remain class members. Their ability to share in any future recovery does not depend on serving as lead plaintiff.
What is a lead plaintiff? In the Chemours Company class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Does it cost anything to contact Glancy or participate in this action? Glancy represents The Chemours Company investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery.
Why work with Glancy on the Chemours Company lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Chemours Company class action. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
The Chemours Company case page, Glancy Prongay Wolke & Rotter LLPComplaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington)press releaseThe Chemours Company SEC filings index, EDGARGlancy Prongay Wolke & Rotter LLP Contact
New York, New York--(Newsfile Corp. - October 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.
Chemours Case Details
The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:
Defendants had materially overstated aftermarket demand for their Opteon products; demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and as a result, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Chemours Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Chemours Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318451
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW ORLEANS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.
Get Help
Chemours investors should visit us at https://claimsfiler.com/cases/nyse-cc-3/ or call toll-free (833) 538-3601. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” CFO Shane Hostetter added that, “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year.”
On this news, the price of Chemours’ shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
Key Dates and Disclosure Events Shareholders Need to Know. The complaint traces how Chemours allegedly reaffirmed its 2026 outlook from February through May while an oversupplied Opteon aftermarket channel was allegedly eroding the demand behind it.
, /PRNewswire/ -- SueWallSt reminds purchasers of The Chemours Company (NYSE: CC) securities of a pending class action on behalf of investors who bought between February 20, 2026 and August 4, 2026 and suffered losses. YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you could be eligible to recover, or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Chemours timeline of disclosure events, in brief: On February 20, 2026, Chemours guided to 2026 adjusted EBITDA of $800 million to $900 million. On August 4, 2026, it cut that range to $775 million to $825 million, and by the August 5 close CC shares had fallen $3.34, or 18.63%, to $14.59. Investors have until December 7, 2026 to seek lead plaintiff status.
February 20 to May 7, 2026: Confidence Restated as Warning Signs Multiplied
The lawsuit chronicles a Class Period that opened with a record fourth quarter for Opteon refrigerants, growth that management tied to AIM Act adoption, and stated confidence in the full-year guide. On May 5, Chemours posted $1.4 billion in first-quarter net sales with record TSS results and reaffirmed its outlook, citing higher TSS demand.
Two days later, management acknowledged that about $10 million of adjusted EBITDA impact had been pulled forward into the first quarter, yet held the forecast and described a strong aftermarket position. It is alleged that aftermarket demand was already decreasing during this stretch because Opteon products had been oversold in 2025.
August 4 and 5, 2026: The Outlook Resets
After the August 4 close, Chemours reported second-quarter net sales of $1.6 billion, down about 1%, on a 4% volume decline it attributed to lower Opteon aftermarket sales against elevated 2025 demand from the initial channel fill. On the next morning's call, management described an oversupplied channel heading into 2026 and pointed to customer prebuying in 2025. As set forth in the complaint, these disclosures corrected prior alleged misstatements about demand and guidance.
"Timely disclosure of material developments is fundamental to fair and efficient markets. The complaint alleges that Chemours held its full-year outlook in May even after noting demand pulled into the first quarter, and investors deserve to know whether the risks described in August were apparent sooner." -- Joseph E. Levi, Esq.
Measuring the Chemours Timeline: Disclosure Events in Days
74 days separated the February 20 outlook from its May 5 reaffirmation, a span in which the complaint alleges aftermarket demand was already declining.
2 days passed between that reaffirmation and the call that flagged a first-quarter demand pull-forward.
91 days elapsed between the May 5 reaffirmation and the August 4 guidance cut.
One trading session separated the after-hours August 4 release from the August 5 repricing.
65 days after the cut, on October 8, 2026, the complaint was filed in the U.S. District Court for the District of Delaware.
Calculate your potential recovery or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the CC Lawsuit
Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements regarding aftermarket demand for its Opteon refrigerant products and the reliability of its 2026 financial guidance during the Class Period. When a reduced full-year adjusted EBITDA outlook and an oversupplied Opteon aftermarket channel were disclosed, the stock price declined sharply.
Q: When did The Chemours Company allegedly mislead investors? A: The Class Period runs from February 20, 2026 to August 4, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.
Q: What court was the CC class action filed in? A: The case was filed in the United States District Court for the District of Delaware, governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in The Chemours to Contact Him Directly to Discuss Their Options
New York, New York--(Newsfile Corp. - October 22, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against The Chemours Company ("the Chemours" or the "Company") (NYSE: CC).
[You may also click here for additional information]
WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the "Class Period").
WHAT TO DO NEXT: To learn more about the The Chemours class action, go to www.faruqilaw.com/CC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). A class action lawsuit has already been filed.
If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
THE ALLEGATIONS:
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Chemours's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Frequently Asked Questions (FAQ) for Investors Regarding the Chemours Securities Class Action Lawsuit
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Chemours (NYSE: CC) between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
How much did the Chemours stock drop?
Following the alleged corrective disclosures, the Chemours shares fell approximately 18% on August 5, 2026, as described in the complaint.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased the Chemours securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319996
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Did you buy CC securities between February 20, 2026 and August 4, 2026?
Affected CC Investor Summary
Who: The Chemours Company (NYSE: CC) What: Securities fraud class action lawsuit filed Class Period: February 20, 2026 through August 4, 2026 Deadline to Seek Lead Plaintiff Status: December 7, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the reliability of the company's financial guidance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options , /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against The Chemours Company ("Chemours") (NYSE: CC) on behalf of those who purchased or acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Delaware and is captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.). Investors have until December 7, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Chemours securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/cc-the-chemours-company-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=cc&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
To view the Chemours video on YouTube, click here: https://youtu.be/6N2AfSIuXgE
THE CHEMOURS COMPANY CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Chemours is an American chemical company that offers a range of industrial and specialty chemical products for markets including, but not limited to, refrigeration and air conditioning. Chemours's Thermal & Specialized Solutions ("TSS") segment sells its product OpteonTM, a set of refrigeration chemicals with a "near-zero ozone-depletion footprint."
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHY DID CHEMOURS'S STOCK DROP?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results, revealing, among other things, that the company reduced its adjusted EBITDA full year guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and its year-over-year net sales decrease of approximately 1%, to a "4% decrease in volumes." Specifically, it stated that "[t]he volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales."
On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
WHAT THE CHEMOURS COMPANY INVESTORS CAN DO NOW:
File to be lead plaintiff by December 7, 2026. Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you. Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR THE CHEMOURS COMPANY INVESTORS:
Chemours investors may, no later than December 7, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Chemours investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Complaint alleges The Chemours Company misled investors between February 20, 2026 and August 4, 2026; investors may seek lead plaintiff role by December 7, 2026
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought The Chemours Company ("Chemours" or the "Company") (NYSE: CC) securities between February 20, 2026 and August 4, 2026. The Chemours Company case, Darcy v. The Chemours Company et al., was filed on October 8, 2026 in the U.S. District Court District of Delaware (Wilmington) (Case No. 1:26-cv-01299).
Investors who suffered losses on The Chemours Company investments can submit their The Chemours Company loss information here before the December 7, 2026 lead plaintiff deadline.
Key dates in the Chemours Company case
Class period: February 20, 2026 to August 4, 2026 Complaint filed: October 8, 2026 Lead plaintiff deadline: December 7, 2026 What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What is the Chemours Company lawsuit about?
The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The complaint filed against The Chemours Company alleges that, among other things, the Company failed to disclose that Defendants had materially overstated aftermarket demand for their Opteon products. For investors who bought during the class period, the December 7, 2026 deadline is the first major step in this case," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist The Chemours Company investors in potentially pursuing claims to recover their losses.
If you wish to serve as lead plaintiff in the Chemours Company class action, you must move the Court no later than December 7, 2026. To learn more about your rights, visit the Chemours Company case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).
You may retain counsel of your choice. If you bought The Chemours Company securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Chemours Company case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026 and suffered losses may be members of the proposed class in the Chemours Company shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by December 7, 2026.
What is a lead plaintiff? In the Chemours Company class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Do I have to be lead plaintiff to recover? No. A The Chemours Company investor's ability to share in any future recovery does not depend on serving as lead plaintiff. The Chemours Company investors may take no action and remain absent class members.
What is the deadline? Motions to serve as lead plaintiff in the Chemours Company class action must be filed by December 7, 2026.
Does it cost anything to contact Glancy or participate in this action? Glancy represents The Chemours Company investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery.
Can I choose my own lawyer? Yes. The Chemours Company investors may retain counsel of their choice.
Why work with Glancy on the Chemours Company lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Chemours Company lawsuit. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
The Chemours Company case page, Glancy Prongay Wolke & Rotter LLP Complaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington) press release The Chemours Company SEC filings index, EDGAR Glancy Prongay Wolke & Rotter LLP Contact
Charles H. Linehan
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: [email protected]
Telephone: 310-201-9150 | Toll-free: 888-773-9224
www.glancylaw.com
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Complaint alleges The Chemours Company misled investors between February 20, 2026 and August 4, 2026; investors may seek lead plaintiff role by December 7, 2026
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought The Chemours Company ("Chemours" or the "Company") (NYSE: CC) securities between February 20, 2026 and August 4, 2026. The Chemours Company case, Darcy v. The Chemours Company et al., was filed on October 8, 2026 in the U.S. District Court District of Delaware (Wilmington) (Case No. 1:26-cv-01299).
Investors who suffered losses on The Chemours Company investments can submit their The Chemours Company loss information here before the December 7, 2026 lead plaintiff deadline.
Key dates in the Chemours Company case
Class period: February 20, 2026 to August 4, 2026Complaint filed: October 8, 2026Lead plaintiff deadline: December 7, 2026What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What is the Chemours Company lawsuit about?
The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The complaint filed against The Chemours Company alleges that, among other things, the Company failed to disclose that Defendants had materially overstated aftermarket demand for their Opteon products. For investors who bought during the class period, the December 7, 2026 deadline is the first major step in this case," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist The Chemours Company investors in potentially pursuing claims to recover their losses.
If you wish to serve as lead plaintiff in the Chemours Company class action, you must move the Court no later than December 7, 2026. To learn more about your rights, visit the Chemours Company case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).
You may retain counsel of your choice. If you bought The Chemours Company securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Chemours Company case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026 and suffered losses may be members of the proposed class in the Chemours Company shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by December 7, 2026.
What is a lead plaintiff? In the Chemours Company class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Do I have to be lead plaintiff to recover? No. A The Chemours Company investor's ability to share in any future recovery does not depend on serving as lead plaintiff. The Chemours Company investors may take no action and remain absent class members.
What is the deadline? Motions to serve as lead plaintiff in the Chemours Company class action must be filed by December 7, 2026.
Does it cost anything to contact Glancy or participate in this action? Glancy represents The Chemours Company investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery.
Can I choose my own lawyer? Yes. The Chemours Company investors may retain counsel of their choice.
Why work with Glancy on the Chemours Company lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Chemours Company lawsuit. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
The Chemours Company case page, Glancy Prongay Wolke & Rotter LLPComplaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington)press releaseThe Chemours Company SEC filings index, EDGARGlancy Prongay Wolke & Rotter LLPContact
Charles H. Linehan
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: [email protected]
Telephone: 310-201-9150 | Toll-free: 888-773-9224
www.glancylaw.com
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:https://www.prnewswire.com/news-releases/whats-next-for-the-chemours-company-shareholders-after-18-63-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302915787.html
San Diego, California--(Newsfile Corp. - October 21, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons or entities who purchased or otherwise acquired The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). Chemours offers a range of industrial and specialty chemical products for markets including, as relevant here, refrigeration and air conditioning.
The Chemours Company faces allegations that it materially overstated market demand for its products.
Investors who purchased Chemours securities during the Class Period and suffered significant losses should contact Robbins LLP for information about the lawsuit and the December 7, 2026 lead plaintiff motion deadline.
Why Was Chemours Sued?
The complaint alleges that, during the Class Period, defendants failed to disclose that:
defendants had materially overstated aftermarket demand for their Opteon products; demand for such products was decreasing because of defendants' overselling Opteon products in the preceding fiscal year;as a result of these undisclosed issues, defendants' financial guidance for the 2026 fiscal year was unreliable; and as a result, defendants' public statements were materially false and misleading at all relevant times.Why Did Chemours Stock Drop?
Plaintiff alleges that on August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, on the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year." On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
Listen to Our Podcast
What Can Chemours Shareholders Do Now?
Investors who purchased or otherwise acquired The Chemours Company securities during the Class Period may be eligible to serve as lead plaintiff. The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to seek appointment as lead plaintiff must move the court no later than December 7, 2026. Contact Robbins LLP for information about the appointment process.
Shareholders do not need to serve as lead plaintiff to share in any potential recovery. Investors who do not seek appointment may remain absent class members.
Does It Cost Anything to Participate?
No. Robbins LLP represents investors on a contingency fee basis, with no upfront or out-of-pocket fees or expenses.
Contact Robbins LLP
Investors seeking additional information about The Chemours Company securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.
Why Robbins LLP?
A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.
"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against The Chemours Company settles, or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Facebook
LinkedIn
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320246
Source: Robbins LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its third quarter 2026 financial results after market on Monday, November 2, 2026.
The Company expects to hold its conference call to discuss its third quarter 2026 financial results at 8:00 a.m. Eastern Standard Time on Tuesday, November 3, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.
Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.
Replay: A webcast replay will be available at investors.chemours.com.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company ("The Chemours" or the "Company") (NYSE: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Promise vs. Reality: The Chemours Performance Gap. Management cited "very stable volume" in May, but the lawsuit alleges an oversold Opteon aftermarket channel was already eroding 2026 demand.
, /PRNewswire/ -- Levi & Korsinsky, LLP highlights the alleged Chemours promise-reality gap at the center of a securities fraud class action pending on behalf of investors who suffered losses after purchasing The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026. Check if you might be eligible to recover your investment losses, or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
The promise, delivered by management in May, was "very stable volume" and a reaffirmed full-year adjusted EBITDA outlook of $800 million to $900 million. The reality came on August 4, 2026, when the Company reported a 4% volume decline and cut that outlook to $775 million to $825 million, and the next day shares fell $3.34, or 18.63%, to close at $14.59. LEAD PLAINTIFF DEADLINE: December 7, 2026.
The Promise
Opteon refrigerants were cast as the Company's growth engine throughout the first half of 2026. In February, the Company projected that double-digit year-over-year Opteon Refrigerant growth would continue into the second quarter. By the first-quarter call, management was claiming "a really, really strong position in the aftermarket" and reaffirming 3% to 5% full-year net sales growth.
Promise vs. Actual: By the Numbers
Volume: "Very stable," according to management in May. Company-wide second-quarter volumes fell 4%. Net sales: Full-year growth of 3% to 5% promised. Second-quarter net sales came in at $1.6 billion, down approximately 1% year over year. Opteon trajectory: Double-digit growth projected into the second quarter. The August results instead identified lower Opteon blends aftermarket sales as the primary driver of the volume decline. Aftermarket demand: Management saw "a lot of upside in the aftermarket as new equipment gets installed." The Company later compared aftermarket sales against "elevated demand" in the prior-year quarter tied to the initial channel fill. Full-year earnings: Adjusted EBITDA of $800 million to $900 million, reaffirmed in May. Cut to $775 million to $825 million in August, removing $75 million from the top of the range. What the Lawsuit Alleges About the Chemours Promise-Reality Gap
Plaintiffs contend that the gap shows these assurances were given while Opteon aftermarket demand was already declining because the Company had oversold product in 2025. The complaint alleges that customer prebuy and initial channel fill pulled sales out of 2026, leaving the original guidance without a reasonable basis. Investors who paid prices allegedly inflated by those statements absorbed the decline once the shortfall surfaced.
"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. The complaint alleges Chemours described its volume as very stable roughly three months before reporting a 4% decline. Shareholders who relied on that assurance deserve answers about what was known when it was given." -- Joseph E. Levi, Esq.
Learn more about the case or call (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com | Attorney Advertising. Prior results do not guarantee similar outcomes.
Frequently Asked Questions About the CC Lawsuit
Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements during the Class Period regarding aftermarket demand for its Opteon refrigerants, the effect of 2025 overselling on 2026 demand, and the reliability of its 2026 financial guidance. When Chemours cut its full-year adjusted EBITDA guidance and attributed lower Opteon aftermarket sales to an oversupplied channel, the stock price declined sharply.
Q: When did Chemours allegedly mislead investors? A: The Class Period runs from February 20, 2026 to August 4, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.
Q: What court was the CC class action filed in? A: The case was filed in the United States District Court for the District of Delaware, governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
CC Shareholder Alert: The Chemours Company Securities Class Action Lawsuit - Investors With Losses May Contact Levi & KorsinskyPR Newswire
NEW YORK, Oct. 21, 2026
Promise vs. Reality: The Chemours Performance Gap. Management cited "very stable volume" in May, but the lawsuit alleges an oversold Opteon aftermarket channel was already eroding 2026 demand.
, /PRNewswire/ -- Levi & Korsinsky, LLP highlights the alleged Chemours promise-reality gap at the center of a securities fraud class action pending on behalf of investors who suffered losses after purchasing The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026. Check if you might be eligible to recover your investment losses, or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
The promise, delivered by management in May, was "very stable volume" and a reaffirmed full-year adjusted EBITDA outlook of $800 million to $900 million. The reality came on August 4, 2026, when the Company reported a 4% volume decline and cut that outlook to $775 million to $825 million, and the next day shares fell $3.34, or 18.63%, to close at $14.59. LEAD PLAINTIFF DEADLINE: December 7, 2026.
The Promise
Opteon refrigerants were cast as the Company's growth engine throughout the first half of 2026. In February, the Company projected that double-digit year-over-year Opteon Refrigerant growth would continue into the second quarter. By the first-quarter call, management was claiming "a really, really strong position in the aftermarket" and reaffirming 3% to 5% full-year net sales growth.
Promise vs. Actual: By the Numbers
Volume: "Very stable," according to management in May. Company-wide second-quarter volumes fell 4%.Net sales: Full-year growth of 3% to 5% promised. Second-quarter net sales came in at $1.6 billion, down approximately 1% year over year.Opteon trajectory: Double-digit growth projected into the second quarter. The August results instead identified lower Opteon blends aftermarket sales as the primary driver of the volume decline.Aftermarket demand: Management saw "a lot of upside in the aftermarket as new equipment gets installed." The Company later compared aftermarket sales against "elevated demand" in the prior-year quarter tied to the initial channel fill.Full-year earnings: Adjusted EBITDA of $800 million to $900 million, reaffirmed in May. Cut to $775 million to $825 million in August, removing $75 million from the top of the range.What the Lawsuit Alleges About the Chemours Promise-Reality Gap
Plaintiffs contend that the gap shows these assurances were given while Opteon aftermarket demand was already declining because the Company had oversold product in 2025. The complaint alleges that customer prebuy and initial channel fill pulled sales out of 2026, leaving the original guidance without a reasonable basis. Investors who paid prices allegedly inflated by those statements absorbed the decline once the shortfall surfaced.
"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. The complaint alleges Chemours described its volume as very stable roughly three months before reporting a 4% decline. Shareholders who relied on that assurance deserve answers about what was known when it was given." -- Joseph E. Levi, Esq.
Learn more about the case or call (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com | Attorney Advertising. Prior results do not guarantee similar outcomes.
Frequently Asked Questions About the CC Lawsuit
Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements during the Class Period regarding aftermarket demand for its Opteon refrigerants, the effect of 2025 overselling on 2026 demand, and the reliability of its 2026 financial guidance. When Chemours cut its full-year adjusted EBITDA guidance and attributed lower Opteon aftermarket sales to an oversupplied channel, the stock price declined sharply.
Q: When did Chemours allegedly mislead investors? A: The Class Period runs from February 20, 2026 to August 4, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.
Q: What court was the CC class action filed in? A: The case was filed in the United States District Court for the District of Delaware, governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cc-shareholder-alert-the-chemours-company-securities-class-action-lawsuit---investors-with-losses-may-contact-levi--korsinsky-302915103.html
New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Chemours and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 7, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, on August 4, 2026, after market, Chemours announced second quarter 2026 financial results. Among other things, the Company allegedly reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management allegedly admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; and (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
Key Details of the Chemours ($CC) Class Action:
Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon productsStock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.
Why is Chemours Being Sued for Securities Fraud?
Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.
According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the “sustained double-digit” Opteon expansion would be “driven by the continued regulatory adoption” of the AIM Act. What’s more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by “higher . . . demand” in its Opteon segment.
As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an “oversupplied channel heading into 2026.”
Why did Chemours’s Stock Drop?
On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had “built additional inventory” of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an “oversupplied channel heading into 2026.”
On this news, Chemours’s stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.
Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
What Can You Do?
If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Or contact:
Adam McCall
[email protected]
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.
Chemours Case Details
The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:
(1) Defendants had materially overstated aftermarket demand for their Opteon products;
(2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year;
(3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and
(4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
What's Next for Chemours Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Chemours Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
NEW YORK and NEW ORLEANS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Companyif they purchased or otherwise acquired the Company’s securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.
What You May Do
If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3616 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026.
>>>CLICK HERE for more information
About the Lawsuit
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” CFO Shane Hostetter added that, “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year.”
On this news, the price of Chemours’ shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.
>>>To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
>>>For More Information about the case, Click HERE
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner [email protected]
1-833-538-3616
1100 Poydras St., Suite 960
New Orleans, LA 70163
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are an investor who purchased or otherwise acquired Chemours securities during the Class Period, you have until December 7, 2026 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
Chemours offers a range of industrial and specialty chemical products for markets including, as relevant here, refrigeration and air conditioning. Chemours reports financial results from its sales of such products, including Opteon™, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint”, in its Thermal & Specialized Solutions segment.
In December 2020, the U.S. Congress enacted the American Innovation and Manufacturing Act (“U.S. AIM Act”), which directed the U.S. Environmental Protection Agency to reduce the human impact on climate change by overseeing the transition to alternative refrigerants that present a lesser impact to the ozone layer than legacy refrigerants.
At all relevant times, Defendants represented to investors that “[g]rowth in our Thermal & Specialized Solutions segment is supported in part by the adoption of the [U.S. AIM Act] in the U.S.”
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
The Chemours Company (NYSE: CC) shareholders should email [email protected] , /PRNewswire/ --
What is the Investigation About?
On August 4, 2026, after the market closed, Chemours announced second-quarter results and reduced its full-year adjusted EBITDA guidance from $800 million–$900 million to $775 million–$825 million. During the earnings call the following morning, management disclosed that customers had accumulated excess inventory of Opteon refrigerants, leaving the aftermarket channel oversupplied heading into 2026.
Following this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
Management identified approximately $65 million in aftermarket sales that it indicated should have been allocated to the current year. Following the disclosures, UBS downgraded Chemours from "Buy" to "Neutral" and reduced its price target by 37.9%, citing analysis indicating that Chemours had oversold products in 2025 and likely early 2026. Morgan Stanley and J.P. Morgan also lowered their price targets.
If you own The Chemours Company (NYSE: CC) securities, please contact Fletcher Moore at [email protected].
You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
MOORE LAW PLLC
30 Wall Street, 8th Floor
New York, NY 10005
[email protected]
www.fmoorelaw.com
Did you buy CC securities between February 20, 2026 and August 4, 2026?
Affected CC Investor Summary
Who: The Chemours Company (NYSE: CC)What: Securities fraud class action lawsuit filedClass Period: February 20, 2026 through August 4, 2026Deadline to Seek Lead Plaintiff Status: December 7, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the reliability of the company’s financial guidanceInvestor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against The Chemours Company (“Chemours”) (NYSE: CC) on behalf of those who purchased or acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Delaware and is captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.). Investors have until December 7, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Chemours securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/cc-the-chemours-company-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=cc&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
THE CHEMOURS COMPANY CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Chemours is an American chemical company that offers a range of industrial and specialty chemical products for markets including, but not limited to, refrigeration and air conditioning. Chemours’s Thermal & Specialized Solutions (“TSS”) segment sells its product Opteon™, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint.”
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHY DID CHEMOURS’S STOCK DROP?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results, revealing, among other things, that the company reduced its adjusted EBITDA full year guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and its year-over-year net sales decrease of approximately 1%, to a “4% decrease in volumes.” Specifically, it stated that “[t]he volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales.”
On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
WHAT THE CHEMOURS COMPANY INVESTORS CAN DO NOW:
File to be lead plaintiff by December 7, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR THE CHEMOURS COMPANY INVESTORS:
Chemours investors may, no later than December 7, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Chemours investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087 [email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Suit alleges The Chemours Company failed to disclose key facts to investors from February 20, 2026 through August 4, 2026; lead plaintiff deadline is December 7, 2026
, /PRNewswire/ -- The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors who acquired its securities from February 20, 2026 through August 4, 2026. The Chemours Company case, Darcy v. The Chemours Company et al., was filed on October 8, 2026 in the U.S. District Court District of Delaware (Wilmington) (Case No. 1:26-cv-01299).
Investors with losses on The Chemours Company securities can contact the Law Offices of Howard G. Smith about the Chemours Company lawsuit before the December 7, 2026 lead plaintiff deadline.
Key deadlines and dates for The Chemours Company investors
Lead plaintiff deadline: December 7, 2026
Class period: February 20, 2026 through August 4, 2026
Complaint filed: October 8, 2026
What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What is the Chemours Company lawsuit about?
The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The lawsuit against The Chemours Company alleges that, among other things, the Company failed to tell investors that Defendants had materially overstated aftermarket demand for their Opteon products. The Chemours Company investors who bought during the class period may be able to pursue their losses, and the December 7, 2026 deadline is where that process begins," said Howard G. Smith of The Law Offices of Howard G. Smith.
Next steps for The Chemours Company investors
The Chemours Company investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims.
Lead plaintiff motions in the Chemours Company class action are due to the Court by December 7, 2026. For more information, visit the firm's website, email [email protected], or call (215) 638-4847.
If you purchased The Chemours Company securities during the class period, you may retain counsel of your choice, or you may take no action and remain an absent class member. No class has been certified in the Chemours Company case so far.
Common questions from The Chemours Company investors
Who is eligible? Investors who acquired The Chemours Company securities from February 20, 2026 through August 4, 2026 and suffered losses may qualify for the class in the Chemours Company shareholder lawsuit.
What is the deadline? Lead plaintiff motions in the Chemours Company case are due by December 7, 2026.
Can I recover without being lead plaintiff? Yes, The Chemours Company investors may take no action and remain absent class members.
Does it cost anything? The Law Offices of Howard G. Smith works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval.
About The Law Offices of Howard G. Smith
The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.
Prior results do not guarantee a similar outcome.
Related links
The Chemours Company case page, The Law Offices of Howard G. Smith
Complaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington)
press release
The Chemours Company SEC filings index, EDGAR
The Law Offices of Howard G. Smith
Contact
Howard G. Smith
The Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, PA 19020
Email: [email protected]
Telephone: (215) 638-4847
www.howardsmithlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in The Chemours Company (NYSE: CC) of a pending securities class action concerning the specialty chemicals company's 2026 EBITDA guidance. Class Period: February 20, 2026 through August 4, 2026. Check if you might be eligible to recover your investment losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Chemours cut its full-year adjusted EBITDA guidance from $800 million-$900 million to $775 million-$825 million, a $50 million reduction at the midpoint. CC shares dropped 18.63% on the news. The deadline to apply for lead plaintiff appointment is December 7, 2026.
"Investors deserve transparency about material risks that could affect their investments, including whether a full-year forecast already reflected sales booked in the prior year. The complaint raises serious questions about whether Chemours' reaffirmed $800 million to $900 million range accounted for the 2025 aftermarket channel fill the Company later described," said Joseph E. Levi, Esq.
The Alleged North American Aftermarket Prebuy Concentration
Management introduced the full-year range on February 19, 2026. During that call, an analyst asked how quarterly earnings would climb from a first-quarter midpoint near $135 million to roughly $200 million by midyear. Management replied, "We have full confidence in our full year guide," and said it expected "earnings growth in all 3 of our businesses."
The lawsuit asserts that this confidence lacked a reasonable basis because North American distributors and technicians had already stocked up on Opteon blends during 2025. The outlook was reaffirmed on May 5, 2026, with management pointing to higher demand in the Thermal & Specialized Solutions (TSS) refrigerant segment. As alleged, the guidance was set too aggressively from the start because it treated pulled-forward sales as recurring demand.
AIM Act Channel Fill and Chemours' 2026 EBITDA Guidance
The U.S. AIM Act, enacted in December 2020, directs the EPA to oversee a shift away from legacy refrigerants. Chemours serves that transition with its Opteon line.SEC filings stated that TSS growth "is supported in part by the adoption of the [U.S. AIM Act] in the U.S."The Company's second quarter 2026 results release stated that the stationary air conditioning transition triggered an "initial aftermarket channel fill" in 2025.The action claims customer prebuy shifted sales out of 2026 and into 2025. The suit alleges the original outlook did not reflect this timing effect.Even the top of the revised $775 million to $825 million range falls below the original $850 million midpoint.
Learn more about the case or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the CC Lawsuit
Q: What is the CC lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is December 7, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: How much did CC stock drop? A: Shares fell approximately 18.63%, a decline of $3.34 per share, after the Company disclosed a reduced full-year 2026 adjusted EBITDA outlook and lower Opteon aftermarket sales tied to the 2025 aftermarket channel fill. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.
Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements regarding aftermarket demand for its Opteon refrigerant products and the reliability of its 2026 financial guidance during the Class Period. When the guidance reduction and the 2025 aftermarket channel fill were disclosed, the stock price declined sharply.
Q: What do CC investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.
Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products.
, /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
Key Details of the Chemours ($CC) Class Action:
Lead Plaintiff Deadline: December 7, 2026
Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products
Stock Drop: August 5, 2026 – 18.63% Stock Drop
Court: U.S. District Court for the District of Delaware
Action: Contact BFA Law to discuss your rights
Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.
Why is Chemours Being Sued for Securities Fraud?
Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.
According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by "higher . . . demand" in its Opteon segment.
As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an "oversupplied channel heading into 2026."
Why did Chemours's Stock Drop?
On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had "built additional inventory" of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an "oversupplied channel heading into 2026."
On this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.
Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
What Can You Do?
If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Lawsuit alleges The Chemours Company made misleading statements to investors from February 20, 2026 to August 4, 2026; lead plaintiff motions are due December 7, 2026
, /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors who acquired the Company's securities from February 20, 2026 to August 4, 2026. Filed on October 8, 2026, the case is Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington), Case No. 1:26-cv-01299.
If you lost money on The Chemours Company securities, submit your The Chemours Company loss information by December 7, 2026 to learn about participating in the lawsuit.
The Chemours Company class action timeline
Class period begins: February 20, 2026Class period ends: August 4, 2026Complaint filed: October 8, 2026Lead plaintiff motion deadline: December 7, 2026What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What is the Chemours Company lawsuit about?
The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"According to the complaint filed against The Chemours Company, the Company, among other things, did not disclose that Defendants had materially overstated aftermarket demand for their Opteon products. The December 7, 2026 deadline is a key date for The Chemours Company investors who want a voice in how this case moves forward," said Frank R. Cruz of The Law Offices of Frank R. Cruz.
What should The Chemours Company investors do now?
The Law Offices of Frank R. Cruz can help The Chemours Company investors evaluate potential claims to recover their losses.
Investors who want to serve as lead plaintiff in the Chemours Company class action must file a motion with the Court by December 7, 2026. For more information, visit the Chemours Company case page, email [email protected], or call 310-914-5007.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
Investors may retain counsel of their choice. The Chemours Company investors who bought during the class period may also take no action and remain absent class members. No class has been certified yet in the Chemours Company case.
Questions and answers about the Chemours Company lawsuit
Who is eligible? Investors who bought The Chemours Company securities between February 20, 2026 and August 4, 2026 and lost money may be class members, and may seek lead plaintiff appointment by December 7, 2026.
What does a lead plaintiff do? The lead plaintiff is appointed by the court to represent all class members and direct the Chemours Company class action.
Must I be lead plaintiff to share in a recovery? No, The Chemours Company investors can take no action and remain absent class members.
How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval.
About The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.
Prior results do not guarantee a similar outcome.
Related links
The Chemours Company case page, The Law Offices of Frank R. CruzComplaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington)press releaseThe Chemours Company SEC filings index, EDGARThe Law Offices of Frank R. CruzFollow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:https://www.prnewswire.com/news-releases/what-should-the-chemours-company-investors-know-after-18-63-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302913240.html
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
Lawsuit alleges The Chemours Company made misleading statements to investors from February 20, 2026 to August 4, 2026; lead plaintiff motions are due December 7, 2026
, /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors who acquired the Company's securities from February 20, 2026 to August 4, 2026. Filed on October 8, 2026, the case is Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington), Case No. 1:26-cv-01299.
If you lost money on The Chemours Company securities, submit your The Chemours Company loss information by December 7, 2026 to learn about participating in the lawsuit.
The Chemours Company class action timeline
Class period begins: February 20, 2026 Class period ends: August 4, 2026 Complaint filed: October 8, 2026 Lead plaintiff motion deadline: December 7, 2026 What happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that you think realistically should have been allocated to more of this year."
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What is the Chemours Company lawsuit about?
The Chemours Company securities lawsuit alleges that, between February 20, 2026 and August 4, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about The Chemours Company's business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result, defendants' positive statements about The Chemours Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"According to the complaint filed against The Chemours Company, the Company, among other things, did not disclose that Defendants had materially overstated aftermarket demand for their Opteon products. The December 7, 2026 deadline is a key date for The Chemours Company investors who want a voice in how this case moves forward," said Frank R. Cruz of The Law Offices of Frank R. Cruz.
What should The Chemours Company investors do now?
The Law Offices of Frank R. Cruz can help The Chemours Company investors evaluate potential claims to recover their losses.
Investors who want to serve as lead plaintiff in the Chemours Company class action must file a motion with the Court by December 7, 2026. For more information, visit the Chemours Company case page, email [email protected], or call 310-914-5007.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
Investors may retain counsel of their choice. The Chemours Company investors who bought during the class period may also take no action and remain absent class members. No class has been certified yet in the Chemours Company case.
Questions and answers about the Chemours Company lawsuit
Who is eligible? Investors who bought The Chemours Company securities between February 20, 2026 and August 4, 2026 and lost money may be class members, and may seek lead plaintiff appointment by December 7, 2026.
What does a lead plaintiff do? The lead plaintiff is appointed by the court to represent all class members and direct the Chemours Company class action.
Must I be lead plaintiff to share in a recovery? No, The Chemours Company investors can take no action and remain absent class members.
How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval.
About The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.
Prior results do not guarantee a similar outcome.
Related links
The Chemours Company case page, The Law Offices of Frank R. Cruz Complaint: Darcy v. The Chemours Company et al., U.S. District Court District of Delaware (Wilmington) press release The Chemours Company SEC filings index, EDGAR The Law Offices of Frank R. Cruz Follow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - October 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company ("The Chemours" or the "Company") (NYSE: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results, including a reduction of its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously), and management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding The Chemours's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the The Chemours class action, go to www.faruqilaw.com/CC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the The Chemours Securities Class Action Lawsuit:
What is the The Chemours securities fraud lawsuit about?
The lawsuit alleges that The Chemours Company ("Chemours") and certain of its officers and directors made materially false and/or misleading statements and failed to disclose material information to investors during the Class Period. Specifically, the complaint alleges that Defendants materially overstated aftermarket demand for their Opteon products and concealed that demand was declining due to Defendants' alleged overselling of those products in the preceding fiscal year. As a result of these allegedly undisclosed issues, the complaint further alleges that Defendants' financial guidance for fiscal year 2026 was unreliable. On August 4, 2026, after market hours, Chemours allegedly revealed the truth when it announced reduced full-year adjusted EBITDA guidance and management acknowledged that aftermarket customers had built excess inventory following an initial channel fill, creating an oversupplied channel heading into 2026.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired the common stock of The Chemours Company (NYSE: CC) on the open market between February 20, 2026 and August 4, 2026, inclusive, may be eligible to participate in this lawsuit. The class period encompasses all qualifying purchases made during those dates, and eligible investors are encouraged to review the complaint and assess their potential claims. Importantly, investors do not need to seek appointment as lead plaintiff in order to participate in the case or share in any potential recovery. Any investor who believes they may have suffered losses as a result of the alleged misconduct is encouraged to contact counsel to learn more about their rights and options.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy and the selection of counsel. Any member of the proposed class may move the court for appointment as lead plaintiff, and the court will typically appoint the applicant or group of applicants who demonstrate the largest financial interest in the relief sought and who otherwise satisfy the requirements of the applicable law. The deadline to file a motion for appointment as lead plaintiff in this action is December 7, 2026. Critically, an investor need not serve as lead plaintiff to be a member of the class or to share in any recovery that may be obtained; class membership and any resulting recovery are available to all eligible investors regardless of whether they seek a leadership role in the case.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased The Chemours securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319734
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 20, 2026 to August 4, 2026
DEADLINE: December 7, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Chemours overstated the demand for its Opteon products. The Company suffered from slowing demand due to overselling in the prior year. The Company's fiscal guidance for 2026 was unreliable. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Chemours, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
CC Investors Have Opportunity to Lead The Chemours Company Securities Fraud Lawsuit with SBS LawPR Newswire
LOS ANGELES, Oct. 19, 2026
, /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 20, 2026 to August 4, 2026
DEADLINE: December 7, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Chemours overstated the demand for its Opteon products. The Company suffered from slowing demand due to overselling in the prior year. The Company's fiscal guidance for 2026 was unreliable. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Chemours, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
View original content:https://www.prnewswire.com/news-releases/cc-investors-have-opportunity-to-lead-the-chemours-company-securities-fraud-lawsuit-with-sbs-law-302912887.html
New York, New York--(Newsfile Corp. - October 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.
Chemours Case Details
The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:
Defendants had materially overstated aftermarket demand for their Opteon products; demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and as a result, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Chemours Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Chemours Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318450
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP reminds purchasers of The Chemours Company (NYSE: CC) securities of a pending securities class action. THE CASE: Investors who bought Chemours securities between February 20, 2026 and August 4, 2026 may be entitled to compensation without payment of any out-of-pocket fees. YOUR OPTIONS: Find out if you might qualify for recovery or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
Management later estimated that roughly $65 million in Opteon aftermarket sales booked in 2025 should have been allocated more to 2026. CC shares fell $3.34 per share, or 18.63%, following the Company's August 4, 2026 second-quarter report. Investors have until December 7, 2026 to seek lead plaintiff status.
TSS Channel Inventory and the Aftermarket Distributor Network
Chemours earns its Opteon refrigerant revenue through the Thermal & Specialized Solutions (TSS) segment, selling to equipment makers and to aftermarket distributors who supply HVAC technicians. As alleged, that structure means distributor purchases made ahead of need can pull sales forward from one year into the next. The filing states that as the U.S. AIM Act drove a residential air-conditioning equipment transition, Chemours moved quickly to keep distributors and technicians well supplied.
Plaintiffs allege that aftermarket customers built extra inventory during that push, leaving the channel oversupplied heading into 2026. According to the lawsuit, the Company nonetheless described TSS aftermarket demand as strong throughout the Class Period without disclosing the overstock.
The Alleged Aftermarket Volume Reversal Behind the TSS Slowdown
When Chemours released second-quarter results, it attributed a volume decline primarily to lower TSS Opteon blends aftermarket sales, measured against elevated prior-year demand from the initial aftermarket channel fill. As set forth in the complaint, management attributed the gap to customers buying ahead in 2025 amid market supply constraints, a comparison it said would weigh on both the second and third quarters of 2026.
Alleged TSS Channel Fill Impact by the Numbers
4%: Second-quarter 2026 volume decline, which the Company attributed primarily to lower Opteon blends aftermarket sales.$1.6 billion: Second-quarter 2026 net sales, down approximately 1% from the prior-year quarter.About $10 million: Adjusted EBITDA impact from TSS demand pulled forward into the first quarter of 2026, as disclosed in May 2026.$210 million to $225 million: Second-quarter TSS adjusted EBITDA range projected in May 2026, a forecast the complaint says was presented as supported by strength across Opteon and Freon refrigerant channels. "The complaint raises serious questions about whether investors received accurate information about how much Opteon inventory was already sitting with Chemours' aftermarket distributors. As alleged, the channel had been stocked ahead of demand in 2025 even as the Company projected continued TSS growth into 2026." -- Joseph E. Levi, Esq.
Submit your information now or call (212) 363-7500.
WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors. Investors who suffered losses have until December 7, 2026 to seek appointment as lead plaintiff.
Frequently Asked Questions About the CC Lawsuit
Q: How much did CC stock drop? A: Shares fell approximately 18.63%, a decline of $3.34 per share, after the Company disclosed second-quarter 2026 results that reduced full-year adjusted EBITDA guidance and attributed lower Opteon aftermarket sales to an oversupplied distribution channel. Investors who purchased shares during the Class Period at allegedly artificially inflated prices and suffered losses may be eligible to seek compensation.
Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements regarding aftermarket demand for its Opteon refrigerant products and the reliability of its 2026 financial guidance during the Class Period. When reduced guidance and lower Opteon aftermarket sales tied to an oversupplied channel were disclosed, the stock price declined sharply.
Q: When did The Chemours Company allegedly mislead investors? A: The Class Period runs from February 20, 2026 to August 4, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.
Q: What documents do I need to submit my information? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm announces that a securities class action lawsuit has been filed in the United States District Court for the District of Delaware on behalf of all persons or entities who purchased or otherwise acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the Class Period).
Investors who purchased Chemours shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for December 7, 2026.
PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION
The filed Complaint alleges that Defendants failed to disclose to investors that:
Defendants had materially overstated aftermarket demand for their Opteon products;demand for such products was decreasing because of Defendants overselling Opteon products in the preceding fiscal year;because of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; andas a result, Defendants public statements were materially false and misleading at all relevant times. On August 4, 2026, after market hours, Chemours announced second quarter of 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026. Management further disclosed from the Q2 and Q3 perspective, there’s probably about $65 million in aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more this year.”
On this news, Chemours stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
WHY WOLF HALDENSTEIN?
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
There is no cost or obligation to speak with an attorney.
Contact:
Phone: (800) 575-0735 or (212) 545-4774Email: [email protected]Contact Person: Gregory Stone, Director of Case and Financial Analysis Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Chemours and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 7, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, on August 4, 2026, after market, Chemours announced second quarter 2026 financial results. Among other things, the Company allegedly reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management allegedly admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; and (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
Key Details of the Chemours ($CC) Class Action:
Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon productsStock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.
Why is Chemours Being Sued for Securities Fraud?
Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.
According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the “sustained double-digit” Opteon expansion would be “driven by the continued regulatory adoption” of the AIM Act. What’s more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by “higher . . . demand” in its Opteon segment.
As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an “oversupplied channel heading into 2026.”
Why did Chemours’s Stock Drop?
On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had “built additional inventory” of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an “oversupplied channel heading into 2026.”
On this news, Chemours’s stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.
Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
What Can You Do?
If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Or contact:
Adam McCall
[email protected]
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Action reflects Chemours' commitment to innovation, intellectual property protection, our customers, and fair competition in the refrigerants industry
, /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC), a global chemistry company, today announces that it has taken action to protect its intellectual property relating to refrigerant technology during Chillventa 2026 in Nuremberg, Germany. Local courts issued injunctions against four companies infringing upon Chemours' intellectual property and patents of select hydrofluoroolefin (HFO) refrigerant blends.
This action showcases Chemours' unwavering commitment to protecting its innovation and intellectual property investments in advanced refrigerant technologies and across applications. Enforcing intellectual property rights supports industry-wide innovation, fair competition, our customers, and continued technology development.
"Innovation does not happen by accident; it is built on years of research, development, and investment," said Joseph Martinko, President, Thermal & Specialized Solutions at Chemours. "Protecting intellectual property is essential to preserving incentives for innovation, advancing refrigerant technology, and supporting fair competition. Chemours will continue to take appropriate action to defend its intellectual property rights and protect the innovations that help our customers meet evolving industry needs."
Chemours is actively working with enforcement authorities around the globe and educating customers, vendors, and other stakeholders to raise awareness about these Patent Infringing products and the importance of buying genuine refrigerants.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, new product development, technologies protected by intellectual rights, governing laws and rule regarding the enforcement of intellectual property rights and patent protections, , plans to continue investment in research and development, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, regulatory changes, and changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerPR Newswire
SHANGHAI, Oct. 18, 2026
, /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally advanced or metastatic triple-negative breast cancer (TNBC) as an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress. The study focuses on patients previously treated with an ADC carrying a topoisomerase I inhibitor payload (hereinafter "Topo I ADC-pretreated"). The abstract is now available on the congress website.
The study (CTR20242376) is designed to evaluate the efficacy and safety of 9MW2821 as monotherapy or in combination with a PD-1 monoclonal antibody in patients with locally advanced or metastatic TNBC. As of April 10, 2026, among 60 efficacy-evaluable Topo I ADC-pretreated patients, the objective response rate (ORR) was 30.0%, the disease control rate (DCR) was 80.0%, the median progression-free survival (mPFS) was 3.7 months, the median duration of response (mDOR) was 8.7 months, and the median overall survival (mOS) was not yet mature. No new safety signals were observed during this follow-up period. The study results indicate that 9MW2821 has a manageable safety profile and positive therapeutic effects in patients with TNBC.
In 2024, an estimated 375,800 women in China were newly diagnosed with breast cancer and approximately 73,000 died of the disease[1]. TNBC accounts for approximately 15%–20% of all breast cancers and is highly aggressive with a poor prognosis. Currently, all ADCs approved for TNBC use a topoisomerase I inhibitor payload. After progression on these agents, chemotherapy remains the mainstay of care and new treatment options are urgently needed.
[1] Xia C, Li H, Wu C, Chen W. Cancer burden and control in China. Nat Rev Clin Oncol. 2026. doi:10.1038/s41571-026-01165-8
About 9MW2821
9MW2821 is a Nectin-4-targeting ADC independently developed by Mabwell on its proprietary ADC development platform. It is currently conducting multiple clinical studies for several indications including urothelial carcinoma (UC), cervical cancer (CC), triple-negative breast cancer (TNBC), and esophageal cancer (EC), with a cumulative clinical enrollment of over 2,200 patients. Currently, four pivotal Phase III clinical trials of 9MW2821 are underway, including UC monotherapy and combination therapy, CC monotherapy, and monotherapy for topoisomerase I inhibitor-payload ADC-pretreated TNBC. 9MW2821 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) for UC, both as monotherapy and in combination therapy. It is the first Nectin-4-targeting agent to enter Phase III clinical study in CC, and the first agent of any target to enter Phase III clinical study specifically in patients with Topo I ADC-pretreated TNBC.
The Phase III clinical trials of 9MW2821 for UC monotherapy, UC combination therapy, and CC monotherapy are planned to undergo interim analyses in 2026, and it is expected to, based on the interim analysis data, submit applications for pre-NDA meetings to the CDE under the National Medical Products Administration (NMPA). Multiple Phase I/II clinical trials are ongoing in parallel and progressing rapidly. In addition, the TNBC (Topo I ADC-pretreated) monotherapy has entered into Phase Ib clinical trials in the United States.
About Mabwell
Mabwell (688062.SH, 02493.HK) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell's mission is "Explore Life, Benefit Health" and its vision is "Innovation, from Ideas to Reality." For more information, please visit www.mabwell.com/en.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.
View original content:https://www.prnewswire.com/news-releases/esmo-2026-preview--mabwell-to-present-clinical-results-for-nectin-4-targeting-adc-9mw2821-in-adc-pretreated-triple-negative-breast-cancer-302911988.html
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - October 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company (""The Chemours" or the "Company") (NYSE: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results, including a reduction of its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously), and management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding The Chemours's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the The Chemours class action, go to www.faruqilaw.com/CC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the The Chemours Securities Class Action Lawsuit:
What is the The Chemours securities fraud lawsuit about?
The lawsuit alleges that The Chemours Company ("Chemours") and certain of its officers and directors made materially false and/or misleading statements and failed to disclose material information to investors during the Class Period. Specifically, the complaint alleges that Defendants materially overstated aftermarket demand for their Opteon products and concealed that demand was declining due to Defendants' alleged overselling of those products in the preceding fiscal year. As a result of these allegedly undisclosed issues, the complaint further alleges that Defendants' financial guidance for fiscal year 2026 was unreliable. On August 4, 2026, after market hours, Chemours allegedly revealed the truth when it announced reduced full-year adjusted EBITDA guidance and management acknowledged that aftermarket customers had built excess inventory following an initial channel fill, creating an oversupplied channel heading into 2026.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired the common stock of The Chemours Company (NYSE: CC) on the open market between February 20, 2026 and August 4, 2026, inclusive, may be eligible to participate in this lawsuit. The class period encompasses all qualifying purchases made during those dates, and eligible investors are encouraged to review the complaint and assess their potential claims. Importantly, investors do not need to seek appointment as lead plaintiff in order to participate in the case or share in any potential recovery. Any investor who believes they may have suffered losses as a result of the alleged misconduct is encouraged to contact counsel to learn more about their rights and options.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy and the selection of counsel. Any member of the proposed class may move the court for appointment as lead plaintiff, and the court will typically appoint the applicant or group of applicants who demonstrate the largest financial interest in the relief sought and who otherwise satisfy the requirements of the applicable law. The deadline to file a motion for appointment as lead plaintiff in this action is December 7, 2026. Critically, an investor need not serve as lead plaintiff to be a member of the class or to share in any recovery that may be obtained; class membership and any resulting recovery are available to all eligible investors regardless of whether they seek a leadership role in the case.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased The Chemours securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319376
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Chemours Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Chemours Company - CCPR Newswire
NEW ORLEANS, Oct. 16, 2026
, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.
Get Help
Chemours investors should visit us at https://claimsfiler.com/cases/nyse-cc-3/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."
On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-the-chemours-company---cc-302911670.html
SummaryChemours is rated 'BUY' with a $20 price target and $30 fair value, reflecting significant undervaluation and recovery potential.CC's investment thesis centers on operating leverage, balance sheet repair, and recovery in non-thermal segments, with normalized EPS targeted at $2.5/share.Despite current elevated leverage (4.4x) and declining earnings, CC's debt reduction and EBITDA improvement could drive re-rating and substantial upside by 2027-2028E.CC remains speculative, but ongoing deleveraging, EBITDA growth, and improved FCF could transition it to a standard investment as key metrics are achieved.Looking for more investing ideas like this one? Get them exclusively at Wolf of Value. Learn More »35.5K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of CC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment.
Short-term trading, options trading/investment and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding for the necessary risk tolerance involved.
I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about.
Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company's domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.
Get Help
Chemours investors should visit us at https://claimsfiler.com/cases/nyse-cc-3/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."
On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
Did you buy CC securities between February 20, 2026 and August 4, 2026?
Affected CC Investor Summary
Who: The Chemours Company (NYSE: CC)
What: Securities fraud class action lawsuit filed
Class Period: February 20, 2026 through August 4, 2026
Deadline to Seek Lead Plaintiff Status: December 7, 2026
Key Lawsuit Allegations: Material misstatements and/or omissions concerning the reliability of the company's financial guidance
Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options
, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against The Chemours Company ("Chemours") (NYSE: CC) on behalf of those who purchased or acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Delaware and is captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.). Investors have until December 7, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Chemours securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/cc-the-chemours-company-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=cc&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
THE CHEMOURS COMPANY CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Chemours is an American chemical company that offers a range of industrial and specialty chemical products for markets including, but not limited to, refrigeration and air conditioning. Chemours's Thermal & Specialized Solutions ("TSS") segment sells its product Opteon™, a set of refrigeration chemicals with a "near-zero ozone-depletion footprint."
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHY DID CHEMOURS'S STOCK DROP?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results, revealing, among other things, that the company reduced its adjusted EBITDA full year guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and its year-over-year net sales decrease of approximately 1%, to a "4% decrease in volumes." Specifically, it stated that "[t]he volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales."
On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
WHAT THE CHEMOURS COMPANY INVESTORS CAN DO NOW:
File to be lead plaintiff by December 7, 2026.
Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.
Retain counsel of choice or take no action.
THE LEAD PLAINTIFF PROCESS FOR THE CHEMOURS COMPANY INVESTORS:
Chemours investors may, no later than December 7, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Chemours investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
